ストックスクリーナーアプリを入手
0.9934
5.39%
-0.0566
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Uses AI Platform to Accelerate Buntanetap FDA Filing - MyChesCo
Annovis Bio stock reports 862 Phase 3 enrollments - ad-hoc-news.de
Annovis Bio, Inc. Announces Partnership With Weave Bio In Preparation Of NDA For Buntanetap In Alzheimer?s Disease - marketscreener.com
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Australia
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Canada
Annovis Bio partners with Weave Bio for NDA preparation - Investing.com
Annovis Announces Partnership with Weave Bio, AI Regulatory - GlobeNewswire
Annovis Bio announces special shareholder meeting - Bitget
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - ad-hoc-news.de
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Andrews Pitchfork - dars.gov.et
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesMFI Divergence - dars.gov.et
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - Yahoo Finance
Annovis says Alzheimer’s trial is fully enrolled, with data expected in 2027 - Stock Titan
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - theglobeandmail.com
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Trend Continuation Trade - dars.gov.et
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Caledonian Record
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - GlobeNewswire
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
4.22%
大文字化:
|
ボリューム (24 時間):